Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

93 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The assessment of human organic cation transporter 1 (hOCT1) mRNA expression in patients with chronic myelogenous leukemia is affected by the proportion of different cells types in the analyzed cell population.
Racil Z, Razga F, Buresova L, Jurcek T, Dvorakova D, Zackova D, Timilsina S, Cetkovsky P, Mayer J. Racil Z, et al. Among authors: cetkovsky p. Am J Hematol. 2010 Jul;85(7):525-8. doi: 10.1002/ajh.21722. Am J Hematol. 2010. PMID: 20575042 Free PMC article. No abstract available.
Imatinib as the first-line treatment of patients with chronic myeloid leukemia diagnosed in the chronic phase: can we compare real life data to the results from clinical trials?
Zackova D, Klamova H, Dusek L, Muzik J, Polakova KM, Moravcova J, Jurcek T, Dvorakova D, Racil Z, Pospisil Z, Oltova A, Michalova K, Brezinova J, Razga F, Doubek M, Cetkovsky P, Trneny M, Mayer J. Zackova D, et al. Among authors: cetkovsky p. Am J Hematol. 2011 Mar;86(3):318-21. doi: 10.1002/ajh.21942. Epub 2011 Feb 15. Am J Hematol. 2011. PMID: 21328429 Free article. No abstract available.
The predictive value of human organic cation transporter 1 and ABCB1 expression levels in different cell populations of patients with de novo chronic myelogenous leukemia.
Razga F, Racil Z, Machova Polakova K, Buresova L, Klamova H, Zackova D, Dvorakova D, Polivkova V, Cetkovsky P, Mayer J. Razga F, et al. Among authors: cetkovsky p. Int J Hematol. 2011 Sep;94(3):303-306. doi: 10.1007/s12185-011-0924-6. Epub 2011 Sep 8. Int J Hematol. 2011. PMID: 21901397 No abstract available.
Assessment of adenosine triphosphate-binding cassette subfamily B member 1 (ABCB1) mRNA expression in patients with de novo chronic myelogenous leukemia: the role of different cell types.
Racil Z, Razga F, Polakova KM, Buresova L, Polivkova V, Dvorakova D, Zackova D, Klamova H, Cetkovsky P, Mayer J. Racil Z, et al. Among authors: cetkovsky p. Leuk Lymphoma. 2011 Feb;52(2):331-4. doi: 10.3109/10428194.2010.533220. Epub 2010 Dec 6. Leuk Lymphoma. 2011. PMID: 21133723 No abstract available.
Insulin resistance is an underlying mechanism of impaired glucose metabolism during nilotinib therapy.
Racil Z, Koritakova E, Sacha T, Klamova H, Belohlavkova P, Faber E, Rea D, Malaskova L, Prochazkova J, Zackova D, Voglova J, Wącław J, Cetkovsky P, Zak P, Mayer J. Racil Z, et al. Among authors: cetkovsky p. Am J Hematol. 2018 Oct;93(10):E342-E345. doi: 10.1002/ajh.25232. Epub 2018 Aug 31. Am J Hematol. 2018. PMID: 30054949 Free article. No abstract available.
Efficacy and tolerance of dasatinib after imatinib failure or intolerance for patients with chronic myeloid leukemia treated in three different hospitals compare well with results achievable in formal clinical trials.
Zackova D, Klamova H, Muzik J, Cmunt E, Racil Z, Machova Polakova K, Dvorakova D, Jurcek T, Razga F, Cetkovsky P, Dusek L, Mayer J. Zackova D, et al. Among authors: cetkovsky p. Leuk Lymphoma. 2013 Oct;54(10):2310-3. doi: 10.3109/10428194.2013.772173. Epub 2013 Feb 28. Leuk Lymphoma. 2013. PMID: 23373966 No abstract available.
Estimation of current cumulative incidence of leukaemia-free patients and current leukaemia-free survival in chronic myeloid leukaemia in the era of modern pharmacotherapy.
Pavlík T, Janoušová E, Pospíšil Z, Mužík J, Záčková D, Ráčil Z, Klamová H, Cetkovský P, Trněný M, Mayer J, Dušek L. Pavlík T, et al. Among authors: cetkovsky p. BMC Med Res Methodol. 2011 Oct 11;11:140. doi: 10.1186/1471-2288-11-140. BMC Med Res Methodol. 2011. PMID: 21988861 Free PMC article.
Evaluation of 5-year imatinib treatment of 458 patients with CP-CML in routine clinical practice and prognostic impact of different BCR-ABL cutoff levels.
Klamová H, Poláková KM, Mužík J, Ráčil Z, Záčková D, Steinerová K, Karas M, Faber E, Demečková E, Michalovičová-Sninská Z, Voglová J, Demitrovičová L, Mikušková E, Tóthová E, Chudej J, Markuljak I, Cmunt E, Moravcová J, Dvořáková D, Michalová K, Jarošová M, Sťastná MM, Cetkovský P, Dušek L, Koza V, Trněný M, Indrák K. Klamová H, et al. Among authors: cetkovsky p. Cancer Med. 2013 Apr;2(2):216-25. doi: 10.1002/cam4.59. Epub 2013 Feb 21. Cancer Med. 2013. PMID: 23634289 Free PMC article.
93 results